Selective Intra Arterial Infusion Chemotherapy for Malignant Nasal and Paranasal Sinus Tumors

An essential dose of cisplatin for super-selective intra-arterial infusion concomitant with radiotherapy in patient with maxillary squamous cell carcinoma

“…This therapy was tolerated better than was reported with the original RADPLAT (150 mg/m 2 ) [4,5]. Miyajima et al [6] reported 26 patients with sinonasal cancer treated by SSIACRT involving 4 courses of weekly CDDP infusion (100 mg/body). Yoshizaki et al [4] presented a regimen whereby it was determined that a CDDP dose which could be safely infused without local edema was determined to be 100 mg/body and the interval for chemotherapy was set at 2 weeks because one of their 5 patients treated by a higher dose CDDP infusion (150 mg/body) required a tracheostomy.…”

“…In the present study, 2 (20%) of 10 patients experienced grade 3 adverse events. The total number of patients with grade 3 or higher acute toxicity from 3 studies of SSIACRT with a higher CDDP dose (100-120 mg/m 2 ) [5,7,8], estimated at 47 (54.7%) of 86 patients, is significantly higher than in 2 studies of SSIACRT with a lower CDDP dose (100 mg/body) [6], which was reported as 3 (8.3%) of 36 patients (Chi square test; P \ 0.01). This suggests that SSIACRT with a lower CDDP dose might be the least toxic regimen in Japanese patients with sinonasal cancer.…”

“…All 3 patients with N2 tumors died within 8 months after treatment, while 20 patients with N0 tumors had a 67% overall survival rate, and those with N1 tumors (n = 2) had a 100% overall survival rate at 5 years. Miyajima et al [6] reported that the overall survival rate in patients with all sinonasal cancers at 3 years was 64.2%, while in patients with maxillary cancer it was 76%. In the present study, overall and disease-free survival rates at 3 years were 100 and 90%, respectively, suggesting that the SSIACRT regimen with our lower CDDP dose (100 mg/body) might be as effective for patients with N0 and \T4b tumors as other regimens with higher CDDP doses.…”

“…Fujishiro et al [7] showed grade 3 myelosuppresive toxicity in 2 (7.1%) of 14 patients. In SSIACRT with a lower CDDP dose (100 mg/ body), Miyajima et al [6] found a grade 3 hemologic toxic effect in 1 (3.8%) of 26 patients. In the present study, 2 (20%) of 10 patients experienced grade 3 adverse events.…”

“…Among US patients, 15% failed to complete the RADPLAT course [3]. A high proportion of Japanese patients are unable to tolerate the original RADPLAT protocol [4,5], therefore, a SSIACRT protocol with a lower dose of CDDP and simultaneous intravenous infusion of sodium thiosulfate neutralizer has been accepted in Japan [4][5][6][7][8]. Since 2003, our treatment centre has applied a preoperative SSIACRT protocol with biweekly administration of a lower-dose CDDP (100 mg/body, i.e.…”